Recruitment of CXCR4+ type 1 innate lymphoid cells distinguishes sarcoidosis from other skin granulomatous diseases
Journal of Clinical Investigation · 03.09.2024 · 134 (17)
DOI: 10.1172/jci178711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.09.2024. Verfasst von Satish Sati und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Receptors, CXCR4, Sarcoidosis, Immunity, Innate, Granuloma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RRD VA, NIAMS NIH HHS, Berstein Foundation.
Abstract (Originalsprache)
Sarcoidosis is a multiorgan granulomatous disease that lacks diagnostic biomarkers and targeted treatments. Using blood and skin from patients with sarcoid and non-sarcoid skin granulomas, we discovered that skin granulomas from different diseases exhibit unique immune cell recruitment and molecular signatures. Sarcoid skin granulomas were specifically enriched for type 1 innate lymphoid cells (ILC1s) and B cells and exhibited molecular programs associated with formation of mature tertiary lymphoid structures (TLSs), including increased CXCL12/CXCR4 signaling. Lung sarcoidosis granulomas also displayed similar immune cell recruitment. Thus, granuloma formation was not a generic molecular response. In addition to tissue-specific effects, patients with sarcoidosis exhibited an 8-fold increase in circulating ILC1s, which correlated with treatment status. Multiple immune cell types induced CXCL12/CXCR4 signaling in sarcoidosis, including Th1 T cells, macrophages, and ILCs. Mechanistically, CXCR4 inhibition reduced sarcoidosis-activated immune cell migration, and targeting CXCR4 or total ILCs attenuated granuloma formation in a noninfectious mouse model. Taken together, our results show that ILC1s are a tissue and circulating biomarker that distinguishes sarcoidosis from other skin granulomatous diseases. Repurposing existing CXCR4 inhibitors may offer a new targeted treatment for this devastating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
- Duke Molecular Physiology Institute, Durham, North Carolina, USA.
- Singapore Management University, Singapore.
- Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Förderung
- RRD VA
- NIAMS NIH HHS
- Berstein Foundation
- Siegel Foundation
- Dermatology Foundation
- H.T. Leung Foundation
- U.S. Department of Veterans Affairs
Zitieren
APA
Sati, S., Huang, J., Kersh, A. E., Jones, P., Ahart, O., Murphy, C., Prouty, S. M., Hedberg, M. L., Jain, V., Gregory, S. G., Leung, D. H., Seykora, J. T., Rosenbach, M., & Leung, T. H. (2024). Recruitment of CXCR4+ type 1 innate lymphoid cells distinguishes sarcoidosis from other skin granulomatous diseases. Journal of Clinical Investigation, 134(17). https://doi.org/10.1172/jci178711
Vancouver
Sati S, Huang J, Kersh AE, Jones P, Ahart O, Murphy C, et al. Recruitment of CXCR4+ type 1 innate lymphoid cells distinguishes sarcoidosis from other skin granulomatous diseases. Journal of Clinical Investigation. 2024;134(17). doi:10.1172/jci178711
BibTeX
@article{Sati2024,
author = {Sati, Satish and Huang, Jianhe and Kersh, Anna E and Jones, Parker and Ahart, Olivia and Murphy, Christina and Prouty, Stephen M and Hedberg, Matthew L and Jain, Vaibhav and Gregory, Simon G and Leung, Denis H and Seykora, John T and Rosenbach, Misha and Leung, Thomas H},
title = {Recruitment of CXCR4+ type 1 innate lymphoid cells distinguishes sarcoidosis from other skin granulomatous diseases},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {17},
doi = {10.1172/jci178711}
}
EUVIMED